HF-REVERT Trial
Cross-source consensus on HF-REVERT Trial from 1 sources and 7 claims.
1 sources · 7 claims
Background
Other
Other
Highlighted claims
- HF-REVERT was an international, multicenter, randomized, double-blind, placebo-controlled phase 2 trial. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The trial was registered as NCT05350969 on 20 April 2022. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The primary endpoint was percentage change in LVESVI from baseline to 6 months. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Recruitment occurred from July 2022 to March 2024 across 54 sites in eight countries. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The trial randomized 294 eligible patients equally to placebo, CDR132L 5 mg kg−1, or CDR132L 10 mg kg−1. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The modified intention-to-treat population included 280 randomized patients who received at least one dose of study drug. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The trial had a 6-month double-blind treatment period followed by follow-up through month 12. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial